Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Auke Beishuizen, Luciana Vinti, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Franca Fagioli, Constantino Sabado Alvarez, Stephane Ducassou, Salvatore Buffardi, Maitane Andión Catalan, Brad Hoppe, Frank Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Stephen Daw

Blood (2023) 142 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2023-187028

Published: 2023

Journal Articles

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Paul Harker-Murray, Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Bradford S. Hoppe, Julie Lisano, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Kara M. Kelly, Stephen Daw

Blood (2023) 141 (17): 2075–2084.

https://doi.org/10.1182/blood.2022017118

Published: 2023

Includes: Supplemental data

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Maeve A O'Reilly, MB, Dinisha Govender, Ajay Vora, MD, Sujith Samarasinghe, Asim Khwaja, Victoria Grandage, Anupama Rao, Phil Ancliff, Danny Cheng, Ben Carpenter, Stephen Daw, David O'Connor, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 102.

https://doi.org/10.1182/blood.V130.Suppl_1.102.102

Published: 2017

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Poornima Kumar, MBBS, Rebekah Ahmed, MBBS, Renu Riat, MBBS, Kirit M Ardeshna, MD, Stephen Daw, MBChb

Blood (2012) 120 (21): 4784.

https://doi.org/10.1182/blood.V120.21.4784.4784

Published: 2012

Journal Articles

Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.

Ananth G. Shankar, Stephen Daw, Georgina Hall, Stephanie Gorde-Grosjean, Christine Mauz Koerholz, Dieter Korholz, William H. Wallace, Dirk Hasenclever, Judith Landman-Parker

Blood (2006) 108 (11): 2471.

https://doi.org/10.1182/blood.V108.11.2471.2471

Published: 2006

NARROW

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.

Email alerts

ASH Publications

American Society of Hematology

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only